nav-left cat-right
cat-right

Institutional Profile: Sanford-Burnham Sets Up Sho...

  The Sanford-Burnham Medical Research Institute, headquartered in La Jolla, CA, dedicated its new Lake Nona campus in Orlando, FL, last fall. The $85 million building, which opened in April 2009, will employ more than 300 people. Florida attracted Sanford-Burnham in 2006 by offering a $350 million incentive package that included land, construction funds, and in-kind services. The Lake Nona facility is part of...

Eli Lilly and GlaxoSmithKline: A Tale of Two Diffe...

New models for drug development, especially in big pharma, are being experimented by different companies. Eli Lilly (LLY) and GlaxoSmithKline (GSK) have two different models. These models do not throw out the old ones – but do offer additional routes going forward. Lilly has a Phenotypic Drug Discover Initiative, (or PD2), launched in 2009. Lilly solicits compounds from other companies so long as they are in...

Trana Discovery Completes $720,000 Series A Invest...

FOR IMMEDIATE RELEASE PR Log (Press Release) – Dec 21, 2009 – CARY, NC – Trana Discovery, Inc., an infectious disease drug discovery technology company, today announced the completion of its Series A round of funding. To date, the company has raised $720,000 in angel funding to commercialize technology that helps to discover new drugs for the treatment of bacterial, viral, and fungal infectious diseases....

2009: The Year That Was For Pfizer

(RTTNews) – True to expectations, Jeffrey Kindler, the CEO of Pfizer Inc. (PFE | Quote | Chart | News | PowerRating), scripted a new playbook for the drug giant in 2009, accelerating the process of transformation by clinching the largest pharmaceutical deal in nearly a decade. The acquisition of Wyeth for $68 billion earlier this year represents a major move by Pfizer to plug the impending holes in its...

Forma Therapeutics raises $25.5M in Series B round

Forma Therapeutics has closed on a Series B financing that raised a total of $25.5 million. The round was led by new investor Lilly Ventures. Lilly was joined by existing investors Novartis Option Fund and Bio*One Capital of Singapore. Lexington-based Cubist Pharmaceutical, Inc. also joined as a new equity investor through a conversion of a previously issued note. Steve Hall, a venture partner at Lilly Ventures, will join...

Syntopix edges closer to early revenue streams, an...

Specialty antimicrobial research and development company Syntopix (AIM: SYN) took another step closer to commercialising a new product targeting a large consumer healthcare market, reporting good results from the trials of its new compound for the treatment of acneic skin, a condition that affects 85% of the population during their lifetime. Over the course of the trials, formulations using the Syntopix dermatological...
Page 4 of 19« First...23456...10...Last »